In this episode, we sit down with Dr. Eitan Raveh, VP of Clinical Partnerships at NeuraLight, to explore a technology that could reshape how Parkinson's disease is measured and tracked in clinical trials. For nearly four decades, the MDS-UPDRS has been the gold standard for evaluating Parkinson's progression, but a new study suggests that a simple eye-tracking test, administered on a tablet in about ten minutes, may be more sensitive at detecting disease progression than the scale neurologists have relied on for generations. Dr. Raveh walks us through NeuraLight's landmark longitudinal study, what the Amplitude of Saccadic Hypometria actually measures, and why two of the scientists who helped build the MDS-UPDRS are now co-authors on a paper showing it may have met its match. If you follow Parkinson's research, drug development, or the future of digital biomarkers in neurology, this is a conversation you won't want to miss.

In this episode, we explore the costs of clinical trials for both the patients and the drug companies, the risks that can come along with them, and the difficult balance between hope and uncertainty that exists in every study. We'll take a closer look at what it takes to bring a new treatment from the laboratory to the clinic, why so many promising therapies fail, and how the people who participate in clinical trials play a vital role in advancing medical science.

We cover the basics of Parkinson's Disease and Essential Tremor. Whether you've been diagnosed or have a friend or family member with the disease, this podcast is for you.